checkAd
    Startseite > Aktien > BridgeBio Pharma > Nachrichten
    BridgeBio Pharma Aktie
    24,880
     
    USD
    +2,26 %
    +0,550 USD
    Letzter Kurs 02:00:00 Nasdaq
    24,880
     
    USD
    200 STK
    Geldkurs 26.04.24
    24,910
     
    USD
    2.500 STK
    Briefkurs 26.04.24
    ISIN: US10806X1028 · WKN: A2PLX7 · SYM: BBIO · USA

    Neueste Nachrichten

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    10.04.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    07.04.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    20.03.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
    06.03.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Announces Proposed Public Offering of Common Stock
    04.03.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
    04.03.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
    22.02.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
    07.02.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    06.02.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    05.02.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
    02.02.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
    18.01.24 · globenewswire · BridgeBio Pharma